Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst,  Institute of Molecular Immunology, MRI, TUM, Germany.

Bastian Höchst is a distinguished molecular immunologist whose career spans groundbreaking research, impactful teaching, and valuable contributions to the scientific community. His academic journey began with a focus on biology and culminated in a doctorate on immune regulation in liver tumors. As a Research Group Leader at the Technical University of Munich, he investigates the complex interplay of immune cells and tissues in acute and chronic inflammation. His pioneering discoveries, such as the mechanisms governing myeloid suppressor cells and immune-regulatory metabolite transfer, have advanced understanding in the field.

Profile

Google Scholar

🌱 Early Academic Pursuits

Bastian Höchst began his academic journey with a passion for understanding the intricate mechanisms of biology. From 1999 to 2005, he pursued his studies in Biology at the University of Bonn and Hamburg, laying the foundation for his future endeavors in molecular immunology. His academic curiosity led him to pursue a doctorate at the Medical School Hannover under the guidance of Prof. Dr. Tim F. Greten. His doctoral research focused on identifying and characterizing myeloid-derived suppressor cells in patients with hepatocellular carcinoma, marking the beginning of his impactful contributions to the field of immunology.

🔬 Professional Endeavors

Currently serving as a Research Group Leader at the Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich (TUM), Bastian Höchst has dedicated his career to unraveling the complexities of immune regulation. His journey in academia has been marked by significant roles, including his previous tenure as a Research Group Leader at the Institute for Animal Physiology and Immunology, Wissenschaftszentrum Weihenstephan, TUM. Additionally, his postdoctoral fellowship at the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn further honed his expertise in immune mechanisms.

🧪 Contributions and Research Focus

Bastian Höchst’s research delves into immune regulation within acute and chronic inflammatory processes, with a particular focus on tissue-specific mechanisms. He has made groundbreaking discoveries, including elucidating the pathways that govern the generation of myeloid suppressor cells in liver tumors. Furthermore, his innovative work revealed that the intercellular transfer of immune-regulatory metabolites is critical to T-cell effector functions. His research has significantly advanced the understanding of immune responses in disease contexts, bridging gaps in immunological knowledge.

🎓 Teaching and Mentorship

A dedicated educator, Bastian Höchst has been actively involved in teaching since 2010, inspiring students in life sciences programs at TUM. His lectures on topics such as onco-immunology, immune metabolism, and immunotherapy provide invaluable insights to aspiring scientists. Through lab courses on immune cell phenotyping and advanced techniques like spectral flow cytometry, he has empowered students with the skills to explore the complexities of immunology. His teaching contributions extend beyond knowledge dissemination, fostering a generation of critical thinkers and innovators.

📜 Accolades and Recognition

Bastian’s expertise has been recognized through his habilitation and venia legendi for Molecular Immunology, under the mentorship of Prof. Dr. Percy Knolle. His contributions as a scientific reviewer for prestigious journals like Hepatology, Journal of Hepatology, and Frontiers in Immunology further reflect his authority in the field. Additionally, his role in evaluating grant applications for the Deutsche Forschungsgemeinschaft (DFG) underscores his impact on shaping future research initiatives.

🌍 Impact and Influence

Through his research, teaching, and reviews, Bastian Höchst has left an indelible mark on the field of molecular immunology. His work not only uncovers critical mechanisms of immune regulation but also provides pathways for therapeutic advancements in inflammatory and tumor-related conditions. His contributions influence both scientific understanding and practical applications, addressing global challenges in health and disease management.

🌟 Legacy and Future Contributions

Bastian Höchst’s journey is one of passion, discovery, and impact. As he continues to lead groundbreaking research, he sets the stage for a future where immune-based therapies are revolutionized. His legacy lies in his ability to connect fundamental research with real-world applications, inspiring colleagues and mentees alike. With his unwavering commitment to scientific exploration, Bastian Höchst is poised to shape the future of molecular immunology, paving the way for transformative breakthroughs.

Publication

  • A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells
    Authors: B. Höchst, L.A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M.P. Manns, …
    Year: 2008

 

  • Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    Authors: B. Höchst, T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, …
    Year: 2009

 

  • Functional classification of memory CD8+ T cells by CX3CR1 expression
    Authors: J.P. Böttcher, M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Höchst, …
    Year: 2015

 

  • Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
    Authors: B. Höchst, J. Gamrekelashvili, M.P. Manns, T.F. Greten, F. Korangy
    Year: 2011

 

  • S100A9 a new marker for monocytic human myeloid‐derived suppressor cells
    Authors: F. Zhao, B. Höchst, A. Duffy, J. Gamrekelashvili, S. Fioravanti, M.P. Manns, …
    Year: 2012

 

  • Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
    Authors: T. Baumann, A. Dunkel, C. Schmid, S. Schmitt, M. Hiltensperger, K. Lohr, …
    Year: 2020

 

  • Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS
    Authors: D. Yuan, S. Huang, E. Berger, L. Liu, N. Gross, F. Heinzmann, M. Ringelhan, …
    Year: 2017

 

  • Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Authors: T.F. Greten, L.A. Ormandy, A. Fikuart, B. Höchst, S. Henschen, M. Hörning, …
    Year: 2010

 

Conclusion

Bastian Höchst’s career exemplifies dedication to advancing molecular immunology through innovative research, education, and mentorship. His contributions have shaped the understanding of immune responses in disease contexts, offering hope for novel therapeutic approaches. As he continues to lead impactful research and foster new talent, Bastian Höchst remains a visionary in his field, poised to drive future breakthroughs that bridge science and medicine for the benefit of society.

 

Mr. Gan Liu | Gastrointestinal cancer| Best Researcher Award

Mr. Gan Liu | Gastrointestinal cancer| Best Researcher Award

Mr. Gan Liu, the Affiliated Hospital of Qingdao University, China.

liu gan is a dedicated researcher and educator at qingdao university, specializing in gastric cancer diagnostics and treatment. his academic journey laid the foundation for innovative contributions to medical imaging and surgical oncology. through groundbreaking work in radiomics and robotic surgery, he has advanced diagnostic precision and surgical outcomes, significantly influencing global oncology practices. his achievements have garnered widespread recognition, marking him as a leader in his field.

 

profile

Scopus

early academic pursuits

liu gan began his academic journey with a strong foundation in medical sciences, focusing on the complexities of gastric cancer. his early education laid the groundwork for a career driven by curiosity and precision. by immersing himself in medical imaging and oncology, liu honed the skills necessary for innovative research. his dedication to learning and his commitment to advancing healthcare positioned him as a rising scholar in his field.

professional endeavors

liu's career flourished at qingdao university, where he took on pivotal roles in medical research and education. as a leading figure in oncology, he collaborated with multidisciplinary teams to develop advanced diagnostic and treatment protocols for gastric cancer. his expertise in medical imaging, particularly enhanced ct and radiomics, underscored his dedication to leveraging technology for better patient outcomes.

contributions and research focus

liu gan’s research centers on improving diagnostic precision and surgical outcomes for gastric cancer patients. he played a critical role in developing a deep learning radiomics nomogram to predict the response of metastatic lymph nodes to neoadjuvant chemotherapy. his investigations into robotic and laparoscopic total gastrectomy have provided valuable insights into optimizing surgical techniques, contributing significantly to evidence-based practice in oncology.

accolades and recognition

liu’s groundbreaking work has earned him accolades in both national and international academic circles. his contributions to gastric cancer research have been celebrated through awards, publications, and invitations to prestigious conferences. his role as a thought leader in medical imaging and oncology has cemented his reputation as a pioneer in his field.

impact and influence

liu’s work has transformed the understanding and management of gastric cancer, impacting clinical practice and patient care globally. his innovative approaches to medical imaging and surgery have set new standards in oncology. by combining technology with medical expertise, liu has influenced a new generation of researchers and clinicians, inspiring advancements in cancer treatment.

legacy and future contributions

as a dedicated researcher and educator, liu gan’s legacy is one of innovation and excellence. his work continues to inspire future medical breakthroughs, with ongoing projects poised to revolutionize gastric cancer diagnostics and treatments. his vision for integrating artificial intelligence into oncology holds promise for reshaping the future of cancer care.

Publications

  1. Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: A single-center retrospective propensity score matching study
    Authors: Liu, G., Cao, S., Liu, X., Wang, K., Zhou, Y.
    Year: 2025

 

  1. Deep Learning Radiomics Nomogram Based on Enhanced CT to Predict the Response of Metastatic Lymph Nodes to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
    Authors: Zhong, H., Wang, T., Hou, M., Liu, Z., Zhou, Y.
    Year: 2024

 

  1. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis
    Authors: Zhong, H., Liu, X., Tian, Y., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Intraoperative performance and outcomes of robotic and laparoscopic total gastrectomy for gastric cancer: A high-volume center retrospective propensity score matching study
    Authors: Jia, Z., Cao, S., Meng, C., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial
    Authors: Liu, G., Cao, S., Liu, X., Zhong, H., Zhou, Y.
    Year: 2022

 

  1. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: a randomized controlled trial
    Authors: Liu, D., Jing, X., Cao, S., Liu, G., Zhou, Y.
    Year: 2021

 

  1. Overexpression of tumour necrosis factor-α induced protein 8 is associated with prognosis in colon cancer
    Authors: Zhang, X., Li, Z., Sun, Y., Liu, X., Zhou, Y.
    Year: 2021

 

  1. Short- and long-term outcomes associated with enhanced recovery after surgery protocol vs conventional management in patients undergoing laparoscopic gastrectomy
    Authors: Tian, Y.-L., Cao, S.-G., Liu, X.-D., Wang, D.-S., Zhou, Y.-B.
    Year: 2020

Conclusion

liu gan’s legacy reflects a profound commitment to enhancing cancer care through research and innovation. his integration of cutting-edge technologies like artificial intelligence into clinical oncology paves the way for future breakthroughs. by inspiring the next generation of medical professionals and driving impactful healthcare solutions, liu’s work ensures lasting progress in the fight against gastric cancer.